Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 3/20 | 0.31 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30424244 | 1.00 | CYP11B2 (0.35) | CYP11B2MAPK10MMP13USP7RAD51 | |
| SCHEMBL24253578 | 0.84 | KMT2A (0.33) | CYP11B2MMP13RAD51 | |
| SCHEMBL30424099 | 0.84 | KMT2A (0.33) | CYP11B2MMP13RAD51 | |
| SCHEMBL30424672 | 0.81 | KCNH2 (0.35) | CYP11B2MMP13RAD51 | |
| SCHEMBL24253932 | 0.81 | KCNH2 (0.35) | CYP11B2MMP13RAD51 | |
| SCHEMBL24253726 | 0.81 | DPP4 (0.36) | CYP11B2RAD51 | |
| SCHEMBL30423561 | 0.81 | DPP4 (0.36) | CYP11B2RAD51 | |
| SCHEMBL24253724 | 0.80 | HCRTR1 (0.33) | CYP11B2MMP13RAD51 | |
| SCHEMBL30424476 | 0.80 | HCRTR1 (0.33) | CYP11B2MMP13RAD51 | |
| SCHEMBL24253533 | 0.79 | LMNA (0.35) | CYP11B2MMP13RAD51 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| CN-116157404-A | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | 诺华股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | CYP11B2 22/4885MAPK10 4209/4885MMP13 3577/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | CYP11B2 22/4885MAPK10 4209/4885MMP13 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.